Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
about
Antibody biomarkers in CNS demyelinating diseases - a long and winding roadDiagnostic biomarkers in multiple sclerosis.Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.Anti-myelin antibodies in clinically isolated syndrome indicate the risk of multiple sclerosis in a Swiss cohort.Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis.Early treatment of multiple sclerosis: a Latin American experts meeting.What makes a prognostic biomarker in CNS diseases: strategies for targeted biomarker discovery? Part 2: chronic progressive and relapsing disease.Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.Methodological Challenges in Protein Microarray and Immunohistochemistry for the Discovery of Novel Autoantibodies in Paediatric Acute Disseminated Encephalomyelitis.Anti-myelin antibodies in multiple sclerosis: clinically useful?Serum IgG repertoire in clinically isolated syndrome predicts multiple sclerosis.Antimyelin antibodies as predictors of disability after clinically isolated syndrome.
P2860
Q28262403-A509B26E-E3B6-4334-9962-06DC998E8394Q30598338-5C55592F-F93C-417B-9EBD-505E977FDD77Q33513478-EBFED31D-F10E-4AD3-81AA-6CF199869ACAQ34636372-6959E3CC-EC43-42C2-9839-2BE2503C8FABQ34653997-234568E9-55DF-432A-BC1D-4EF20201E0D8Q34654987-66D9D236-901E-4673-9D25-1212ADAB7E3FQ35539775-62DA0759-DFD4-45DD-B7F0-B98299040490Q35542868-2B92A874-A468-4D06-AA8D-AD76B7FDF82DQ37400955-B335E862-7785-4CD6-B540-73C9ABECB86BQ37645629-887D43E0-3439-4514-82E6-B2509C232833Q38088747-A3322CB5-3FBC-4251-9C34-3E8941460282Q38234717-F5A61DEB-FE50-45D3-A3EC-16C6FB32D86CQ38741727-1EDB8B59-7C00-4FB8-8018-9A4D4E2D5896Q42718406-E8FEB086-4F8B-4BDA-B12E-01085703FEEFQ48696793-EDF34344-6389-45A0-B040-C190800C158BQ54538706-70428358-63C3-4441-A10E-B8A295B7A945
P2860
Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antimyelin antibodies and the ...... a primary demyelinating event.
@ast
Antimyelin antibodies and the ...... a primary demyelinating event.
@en
type
label
Antimyelin antibodies and the ...... a primary demyelinating event.
@ast
Antimyelin antibodies and the ...... a primary demyelinating event.
@en
prefLabel
Antimyelin antibodies and the ...... a primary demyelinating event.
@ast
Antimyelin antibodies and the ...... a primary demyelinating event.
@en
P2093
P2860
P356
P1476
Antimyelin antibodies and the ...... a primary demyelinating event.
@en
P2093
P2860
P304
P356
10.1136/JNNP.2005.077784
P407
P577
2006-06-01T00:00:00Z